ALAUNOS THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.65 USD | +3.16% |
|
-0.61% | -38.71% |
| Jun. 10 | BioSig Technologies Appoints Ferdinand Groenewald as Interim CFO | MT |
| May. 15 | Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 264.1 | 847.1 | 536.6 | 234 | 155.4 | 16.98 |
| Enterprise Value (EV) 1 | 202.3 | 769.7 | 426.3 | 187.3 | 135.9 | 10.92 |
| P/E ratio | 1.96 x | -6.73 x | -6.61 x | -2.97 x | -3.74 x | -0.48 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1,809 x | - | - | 588 x | 53.2 x | 3,396 x |
| EV / Revenue | 1,386 x | - | - | 471 x | 46.5 x | 2,184 x |
| EV / EBITDA | -3.79 x | -13.4 x | -5.38 x | -2.52 x | -4.53 x | -0.42 x |
| EV / FCF | -5.04 x | -26.2 x | -11.8 x | -5.36 x | -4.86 x | -2.14 x |
| FCF Yield | -19.8% | -3.82% | -8.45% | -18.7% | -20.6% | -46.7% |
| Price to Book | 3.51 x | 8.99 x | 4.35 x | 4.04 x | 4.03 x | 2.69 x |
| Nbr of stocks (in thousands) | 9,414 | 11,964 | 14,196 | 14,309 | 15,965 | 16,013 |
| Reference price 2 | 28.05 | 70.80 | 37.80 | 16.35 | 9.736 | 1.060 |
| Announcement Date | 3/5/19 | 3/2/20 | 3/1/21 | 3/30/22 | 3/7/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.146 | - | - | 0.398 | 2.922 | 0.005 |
| EBITDA 1 | -53.33 | -57.23 | -79.23 | -74.21 | -29.98 | -26.18 |
| EBIT 1 | -53.91 | -57.86 | -80.36 | -76.81 | -32.74 | -28.49 |
| Operating Margin | -36,921.92% | - | - | -19,298.74% | -1,120.4% | -569,860% |
| Earnings before Tax (EBT) 1 | -53.12 | -117.8 | -79.98 | -78.75 | -37.73 | -35.14 |
| Net income 1 | -53.12 | -117.8 | -79.98 | -78.75 | -37.73 | -35.14 |
| Net margin | -36,381.51% | - | - | -19,786.68% | -1,291.24% | -702,800% |
| EPS 2 | 14.35 | -10.52 | -5.722 | -5.510 | -2.606 | -2.200 |
| Free Cash Flow 1 | -40.13 | -29.4 | -36.02 | -34.94 | -27.95 | -5.097 |
| FCF margin | -27,488.53% | - | - | -8,778.05% | -956.38% | -101,935% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/5/19 | 3/2/20 | 3/1/21 | 3/30/22 | 3/7/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 2.911 | 0.011 | - | 0.004 | - | 0.001 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -10.31 | -9.085 | -9.233 | -8.264 | -8.521 | -9.672 | -7.982 | -8.664 | -7.949 |
| Operating Margin | - | - | - | -283.89% | -77,463.64% | - | -199,550% | - | -794,900% |
| Earnings before Tax (EBT) 1 | -11.79 | -9.788 | -9.932 | -8.851 | -9.159 | -10.05 | -8.773 | -8.476 | -7.843 |
| Net income 1 | -11.79 | -9.788 | -9.932 | -8.851 | -9.159 | -10.05 | -8.773 | -8.476 | -7.843 |
| Net margin | - | - | - | -304.05% | -83,263.64% | - | -219,325% | - | -784,300% |
| EPS 2 | -0.7500 | -0.7500 | -0.7500 | -0.6000 | -0.6000 | -0.6000 | -0.6000 | -0.6000 | -2.090 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/7/23 | 5/10/23 | 8/14/23 | 11/14/23 | 4/1/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 61.7 | 77.4 | 110 | 46.7 | 19.5 | 6.06 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -40.1 | -29.4 | -36 | -34.9 | -27.9 | -5.1 |
| ROE (net income / shareholders' equity) | -80% | -130% | -73% | -86.5% | -78.1% | -157% |
| ROA (Net income/ Total Assets) | -33.6% | -35.4% | -39.3% | -39.8% | -25.6% | -48.7% |
| Assets 1 | 158.2 | 332.5 | 203.4 | 197.8 | 147.3 | 72.22 |
| Book Value Per Share 2 | 8.000 | 7.880 | 8.700 | 4.050 | 2.420 | 0.3900 |
| Cash Flow per Share 2 | 5.770 | 6.610 | 8.070 | 5.310 | 2.450 | 0.3800 |
| Capex 1 | 0.46 | 0.28 | 9.78 | 3.32 | 0.22 | 0.2 |
| Capex / Sales | 314.38% | - | - | 834.92% | 7.39% | 3,940% |
| Announcement Date | 3/5/19 | 3/2/20 | 3/1/21 | 3/30/22 | 3/7/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -38.71% | 10.41M | |
| +15.58% | 121B | |
| +16.60% | 110B | |
| +17.82% | 25.93B | |
| -24.33% | 19.27B | |
| -19.58% | 16.01B | |
| -17.95% | 15.66B | |
| -48.32% | 14.89B | |
| +58.78% | 14.47B | |
| +4.91% | 13.91B |
- Stock Market
- Equities
- TCRT Stock
- Financials Alaunos Therapeutics, Inc.
